Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 161

1.

Genomic testing in myeloid malignancy.

Docking TR, Karsan A.

Int J Lab Hematol. 2019 May;41 Suppl 1:117-125. doi: 10.1111/ijlh.13022.

PMID:
31069982
2.

Endothelial Sash1 Is Required for Lung Maturation through Nitric Oxide Signaling.

Coulombe P, Paliouras GN, Clayton A, Hussainkhel A, Fuller M, Jovanovic V, Dauphinee S, Umlandt P, Xiang P, Kyle AH, Minchinton AI, Humphries RK, Hoodless PA, Parker JDK, Wright JL, Karsan A.

Cell Rep. 2019 May 7;27(6):1769-1780.e4. doi: 10.1016/j.celrep.2019.04.039.

3.

Fixation Effects on Variant-Calling in a Clinical Resequencing Panel.

Parker JDK, Yap SQ, Starks E, Slind J, Swanson L, Docking TR, Fuller M, Zhou C, Walker B, Filipenko D, Xiong W, Karimuddin AA, Phang PT, Raval M, Brown CJ, Karsan A.

J Mol Diagn. 2019 May 2. pii: S1525-1578(18)30196-X. doi: 10.1016/j.jmoldx.2019.03.005. [Epub ahead of print]

PMID:
31055024
4.

Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.

Thibodeau ML, Zhao EY, Reisle C, Ch'ng C, Wong HL, Shen Y, Jones MR, Lim HJ, Young S, Cremin C, Pleasance E, Zhang W, Holt R, Eirew P, Karasinska J, Kalloger SE, Taylor G, Majounie E, Bonakdar M, Zong Z, Bleile D, Chiu R, Birol I, Gelmon K, Lohrisch C, Mungall KL, Mungall AJ, Moore R, Ma YP, Fok A, Yip S, Karsan A, Huntsman D, Schaeffer DF, Laskin J, Marra MA, Renouf DJ, Jones SJM, Schrader KA.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003681. doi: 10.1101/mcs.a003681. Print 2019 Apr.

5.

A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.

Pandoh PK, Corbett RD, McDonald H, Alcaide M, Kirk H, Trinh E, Haile S, MacLeod T, Smailus D, Bilobram S, Mungall AJ, Ma Y, Moore RA, Coope R, Zhao Y, Jones SJ, Holt RA, Karsan A, Morin RD, Marra MA.

Biotechniques. 2019 Feb;66(2):85-92. doi: 10.2144/btn-2018-0148.

6.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
7.

A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.

Alcaide M, Cheung M, Bushell K, Arthur SE, Wong HL, Karasinska J, Renouf D, Schaeffer DF, McNamara S, Tertre MCD, Batist G, Kennecke HF, Karsan A, Morin RD.

J Mol Diagn. 2019 Mar;21(2):214-227. doi: 10.1016/j.jmoldx.2018.09.007. Epub 2018 Nov 23.

PMID:
30472330
8.

High-Resolution Single-Cell DNA Methylation Measurements Reveal Epigenetically Distinct Hematopoietic Stem Cell Subpopulations.

Hui T, Cao Q, Wegrzyn-Woltosz J, O'Neill K, Hammond CA, Knapp DJHF, Laks E, Moksa M, Aparicio S, Eaves CJ, Karsan A, Hirst M.

Stem Cell Reports. 2018 Aug 14;11(2):578-592. doi: 10.1016/j.stemcr.2018.07.003. Epub 2018 Aug 2.

9.

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch'ng C, Thomas R, Ng T, Yip S, Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM.

Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a003327. doi: 10.1101/mcs.a003327. Print 2018 Aug. No abstract available.

10.

Non-invasive prenatal aneuploidy testing: Critical diagnostic performance parameters predict sample z-score values.

Blais J, Giroux S, Caron A, Clément V, Dionne-Laporte A, Jouan L, Gauthier J, MacLeod T, Moore R, Parker J, Swanson L, Zhao Y, Rouleau G, Karsan A, Langlois S, Rousseau F.

Clin Biochem. 2018 Sep;59:69-77. doi: 10.1016/j.clinbiochem.2018.06.015. Epub 2018 Jun 27.

11.

miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling.

Lam J, van den Bosch M, Wegrzyn J, Parker J, Ibrahim R, Slowski K, Chang L, Martinez-Høyer S, Condorelli G, Boldin M, Deng Y, Umlandt P, Fuller M, Karsan A.

Nat Commun. 2018 Jun 20;9(1):2418. doi: 10.1038/s41467-018-04831-3.

12.

Applications of Bayesian network models in predicting types of hematological malignancies.

Agrahari R, Foroushani A, Docking TR, Chang L, Duns G, Hudoba M, Karsan A, Zare H.

Sci Rep. 2018 May 3;8(1):6951. doi: 10.1038/s41598-018-24758-5.

13.

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A.

Curr Oncol. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.

14.

CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.

Cremin C, Howard S, Le L, Karsan A, Schaeffer DF, Renouf D, Schrader KA.

Hered Cancer Clin Pract. 2018 Mar 7;16:7. doi: 10.1186/s13053-018-0088-y. eCollection 2018.

15.

An actionable test using loss of heterozygosity in identifying high-risk oral premalignant lesions.

Liu KYP, Lu XJD, Cheng YL, Klieb H, Ng S, McNeil K, Karsan A, Poh CF.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Dec 18. pii: S2212-4403(17)31208-7. doi: 10.1016/j.oooo.2017.10.019. [Epub ahead of print]

PMID:
29428696
16.

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.

Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.

Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.

17.

Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform.

Chang KTE, Goytain A, Tucker T, Karsan A, Lee CH, Nielsen TO, Ng TL.

J Mol Diagn. 2018 Jan;20(1):63-77. doi: 10.1016/j.jmoldx.2017.09.007. Epub 2017 Nov 20.

18.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

19.

APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.

Yi Y, Tsai SH, Cheng JC, Wang EY, Anglesio MS, Cochrane DR, Fuller M, Gibb EA, Wei W, Huntsman DG, Karsan A, Hoodless PA.

Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. Epub 2017 Oct 24.

PMID:
29079036
20.

Meis2 as a critical player in MN1-induced leukemia.

Lai CK, Norddahl GL, Maetzig T, Rosten P, Lohr T, Sanchez Milde L, von Krosigk N, Docking TR, Heuser M, Karsan A, Humphries RK.

Blood Cancer J. 2017 Sep 29;7(9):e613. doi: 10.1038/bcj.2017.86.

Supplemental Content

Loading ...
Support Center